Last week, Australia's Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnea, a condition in which breathing stops and starts repeatedly during sleep.

The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea. The Food and Drug Administration on Friday authorized the use of Zepbound ...

But the program may be able to cover an obesity medication that treats a secondary condition, like obstructive sleep apnea. Scientists are studying weight loss drugs for a broad array of ...

Zepbound was approved last year to treat obesity. The drug's maker, Eli Lilly, says it reduces the severity of obstructive sleep apnea by 63%.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...

GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.

Last week, Australia's Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnea, a condition in which breathing stops and starts repeatedly during sleep.

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...